Franklin Resources Inc. Acquires 41,632 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Franklin Resources Inc. boosted its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 62.2% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 108,574 shares of the company’s stock after buying an additional 41,632 shares during the period. Franklin Resources Inc. owned approximately 0.15% of Kiniksa Pharmaceuticals International worth $3,004,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Kiniksa Pharmaceuticals International by 4.7% during the first quarter. Vanguard Group Inc. now owns 3,359,101 shares of the company’s stock worth $74,606,000 after acquiring an additional 151,604 shares during the period. Acadian Asset Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 22.6% during the 2nd quarter. Acadian Asset Management LLC now owns 1,267,989 shares of the company’s stock worth $35,067,000 after purchasing an additional 233,668 shares in the last quarter. Millennium Management LLC raised its stake in shares of Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after purchasing an additional 67,452 shares during the period. Nuveen LLC bought a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $16,992,000. Finally, Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Kiniksa Pharmaceuticals International by 56.0% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 623,689 shares of the company’s stock valued at $17,257,000 after purchasing an additional 223,946 shares in the last quarter. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Stock Down 2.1%

Shares of Kiniksa Pharmaceuticals International stock opened at $40.07 on Wednesday. The stock has a market cap of $3.04 billion, a P/E ratio of 89.05 and a beta of 0.02. Kiniksa Pharmaceuticals International, plc has a 12-month low of $17.82 and a 12-month high of $42.98. The business’s 50 day moving average is $39.26 and its 200-day moving average is $33.72.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 28th. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.31 by ($0.08). Kiniksa Pharmaceuticals International had a net margin of 6.01% and a return on equity of 7.46%. The firm had revenue of $180.86 million during the quarter, compared to the consensus estimate of $166.64 million. During the same period in the prior year, the business posted ($0.18) earnings per share. Kiniksa Pharmaceuticals International’s quarterly revenue was up 61.2% compared to the same quarter last year. On average, sell-side analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group lifted their target price on Kiniksa Pharmaceuticals International from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 2nd. Zacks Research cut shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $48.00 target price on shares of Kiniksa Pharmaceuticals International in a research report on Tuesday. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $52.00.

Insider Buying and Selling

In other Kiniksa Pharmaceuticals International news, CAO Michael R. Megna sold 50,490 shares of the business’s stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $38.87, for a total transaction of $1,962,546.30. Following the transaction, the chief accounting officer owned 27,046 shares of the company’s stock, valued at $1,051,278.02. The trade was a 65.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider John F. Paolini sold 82,542 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $37.14, for a total value of $3,065,609.88. Following the completion of the sale, the insider owned 61,324 shares in the company, valued at $2,277,573.36. This represents a 57.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 596,622 shares of company stock worth $22,697,248. Corporate insiders own 53.48% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.